After treat-to-target trial findings showed that mealtime and postprandial treatment with Fiasp resulted in effective glycemic control and safety results similar to slightly slower insulin aspart (Novolog), the FDA has approved Fiasp for use in pediatrics with diabetes.
Fiasp, a rapid-acting human insulin analog, was compared with NovoLog in a randomized trial involving 777 pediatrics (aged 2 to 17 years). There were blind meal injections and open-label postprandial injections. Week 26 of the trial showed both were effective at getting glucose to target.
In children and adolescents with type 1 diabetes, mealtime and postmeal faster aspart with insulin degludec provided effective glycemic control and superior HbA1c with no additional safety risks versus aspart (Novolog).
Read more at PubMed.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
[yikes-mailchimp form=”1″]
